Skip to main content
SpringerLink
Log in

New asthma strategy may reduce growth impairment risk

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske Jr RF, Mauger DT, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bade E, Covar RA, Friedman NJ, Guilbert TW, Heidarian-Raissy H, Kelly HW, Malka-Rais J, Mellon MH, Sorkness CA, Taussig L.Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet: [8 pages], 15 Feb 2011. Available from: URL: doi.org/10.1016/S0140-6736(10)62145-9

  2. Checkley W.New insights into the treatment of persistent asthma. Lancet: [2 pages], 15 Feb 2011. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(10)62313-6

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

New asthma strategy may reduce growth impairment risk. React. Wkly. 1340, 2 (2011). https://doi.org/10.2165/00128415-201113400-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113400-00002

Keywords

Search

Navigation